Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.36 | N/A | +25.50% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $4.36 | N/A | +25.50% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Management expressed satisfaction with the earnings performance, particularly the EPS beat. They emphasized their commitment to innovation and growth.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative therapies.
This earnings report indicates that United Therapeutics is performing well in terms of profitability, as shown by the significant EPS beat. The stock's positive reaction of 2.88% suggests that investors are encouraged by the company's financial health. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RESTAURANT BRANDS IN
Oct 24, 2016